开元官网登录入口

Editor's note:
Recently, MicroPort® MedBot® Group was invited for the second time by the Organizing Committee of the China International Import Expo to participate in the event. This time, the Toumai® Endoscopic Surgical Robot, as a pioneering force in the "Open Development" exhibition commemorating the tenth anniversary of China Pilot Free Trade Zone, made a grand appearance alongside China's major achievements such as the space station, C919 large aircraft, high-temperature gas-cooled reactor nuclear power plant, and "Zuchongzhi No." at the National Comprehensive Pavilion "China Pavilion." During the Expo, Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of the MicroPort® MedBot®, granted an exclusive interview to Xinhua, where he elaborated on the company's exploration of 5G remote surgery, product development and registration, and overseas market layout.

From November 5th to 10th, the 6th China International Import Expo was held in Shanghai. MicroPort® MedBot® Group, as a representative of Chinese innovation in the field of medical robotics, showcased the flagship product Toumai® Endoscopic Surgical Robot, demonstrating the technological prowess. During an interview with Xinhua, Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort® MedBot®, expressed that the company will be guided by clinical applications and target the common needs of the industry, continuously increasing investment in key core technology research and development. The aim is to achieve technological breakthroughs that lead the future development of the industry, continuously promoting the maturity and advancement of Chinese-developed surgical robot technology, and benefiting patients worldwide.

Having appeared twice at the CIIE and resolute in expanding technological presence overseas

We remain committed to openness and mutual benefits. "Participating in the CIIE is a significant opportunity for companies to engage in international exchanges, showcase their technologies, and seek collaboration. It is our second time participating, and we are still filled with excitement and honor," said Yu Liu. During this edition of the CIIE, MicroPort® MedBot® presented its flagship product, the Toumai® surgical robot. Notably, Toumai® is the first Chinese-developed four-arm laparoscopic surgical robot approved by the National Medical Products Administration (NMPA) for market launch. In September of this year, the robot obtained multi-department registration certificates from the NMPA and can be applied in minimally invasive surgeries in fields such as urology, general surgery, thoracic surgery, and gynecology. Equipped with highly flexible articulated surgical instruments, an immersive glasses-free 3D endoscopic system that provides a vivid three-dimensional surgical view, and an intuitive master-slave teleoperation system, Toumai® offers precise control, simplifies surgical procedures, and reduces operation time. Based on clinical data, up until the end of October this year, the Toumai® has performed over 1,500 assisted clinical validation surgeries in more than 50 hospitals across 20 provinces in China, covering complex and challenging procedures in departments including urology, hepatobiliary surgery, gastrointestinal surgery, thoracic surgery, gynecology, and breast surgery. Liu Yu explained that Toumai® has successfully completed all high-difficulty surgical procedures across various departments, setting clinical records as the "first domestically achieved" robot-assisted surgeries in numerous specialties. This achievement demonstrates its excellent clinical adaptability, mature clinical applications, and ability to fully meet the clinical requirements of multiple departments, effectively supporting the high-quality development of clinical practice and research in hospitals.

With the industry gradually maturing and the pace of centralized procurement of high-value medical consumables in China's medical industry accelerating, it has become a trend for Chinese medical devices to "go global". Yu Liu introduced that MicroPort® MedBot® had already laid out the global market at the beginning of its listing. In recent years, it has actively "gone out" through overseas marketing, participation in overseas conferences, application for overseas registration, and overseas machine trials, firmly supporting technology going overseas and strengthening exchanges with doctors at home and abroad. 5G remote healthcare is a direction that MicroPort® MedBot® continues to explore. With the rapid development of modern technology, the medical field has also ushered in revolutionary breakthroughs. Adhering to the belief of " Make surgery easier, safer and less invasive", MicroPort® MedBot® has been focusing on the exploration and practice of 5G remote surgery in recent years.

It is reported that since the completion of the first ultra-long-distance urological surgery in cooperation with Jiangsu Provincial People's Hospital in June 2022, MicroPort® MedBot® has successively cooperated with well-known Chinese top hospitals such as Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Gansu Provincial People's Hospital, First Affiliated Hospital of Zhejiang University School of Medicine, Seventh Medical Center of 301 Hospital, First Affiliated Hospital of Zhengzhou University, Obstetrics and Gynecology Hospital Affiliated to Fudan University, Zhejiang Provincial People's Hospital, Fourth Hospital of Hebei Medical University and Shanghai Chest Hospital, and carried out more than 70 cases of 5G remote robot surgery in Xinjiang, Gansu, Fujian, Henan, Ningxia, Guizhou, Hebei and other places, which widely involved complex surgical procedures in general surgery, urology, thoracic surgery, and gynecology. The farthest surgical distance exceeded 5000 kilometers and created global first or high-difficulty surgery records such as radical prostatectomy, radical nephrectomy, radical cystectomy, hepatectomy, spleen-preserving distal pancreatectomy, radical gastrectomy, hysterectomy, and multiple consecutive radical prostatectomies. Yu Liu introduced that 5G remote surgery can overcome time and space barriers, achieve remote surgical operations, reduce the time and economic cost of patients' medical treatment, achieve early diagnosis and treatment, and reduce the delay of the disease. At the same time, it reduces the disadvantages of uneven distribution of medical resources. Moreover, because surgical robots have high precision, high stability, and high flexibility, they can reduce surgical trauma, blood loss, and infection rate. "5G remote healthcare can achieve national-level high-level hospital support for underdeveloped areas, realize remote sharing of top medical technology, top equipment resources, and top medical teams, which is in line with the strategic policy of national regional medical center construction. Therefore, this is also the direction that MicroPort® MedBot® continues to practice." said Yu Liu.

Focused on Core Technology to Contribute to the Effective Sharing of Medical Resources

In addition to the Toumai® exhibited at CIIE, MicroPort® MedBot® also owns several products such as DFVision® 3D Electronic Laparoscope, SkyWalker™ Orthopedic Surgical Robot, Mona Lisa prostate biopsy robot, R-ONE® vascular interventional surgical robot, and bronchoscope robot. Over the years, MedBot® has focused on the industrialization strategic layout of surgical robot products, covering laparoscopy, orthopedics, vascular intervention, trans-natural orifice, percutaneous puncture, and aesthetic surgery robots, the six "golden tracks", through two modes of independent research and development and international deep industry cooperation.

Yu Liu introduced, "Toumai®, DFVision®, SkyWalker®, and Mona Lisa, have all been approved for marketing by the National Medical Products Administration (NMPA), which has laid an important foundation for the localization and marketization of high-end medical equipment." Looking at the current surgical robot market, domestic laparoscopic robots have the largest share and the number of surgeries is increasing year by year, but the market penetration rate is insufficient and the popularization rate is low. In this regard, Yu Liu said that the surgical robot is a high-threshold field that requires continuous innovation and breakthroughs. To stand out in the field of surgical robots, we need to focus on core technology, solve the pain points of enterprises and hospitals, embed the experience of doctors into products, thereby improving the competitiveness and added value of products, and meeting market demands and expectations. Regarding the development plan of MicroPort® MedBot®, Yu Liu shared, "Our plan is to continue to deepen the six major robot surgery fields, polish products, delve into technical research and development, bring a better operation experience to the clinic, and bring the convenience of intelligent technology to patients. By strengthening medical engineering cooperation, fully listening to clinical needs, constantly absorbing feedback suggestions, and promoting continuous optimization and iteration of products in all tracks." At the same time, Yu Liu said that the future direction of Chinese surgical robots is not only intelligent, but should also be inclusive, and services should sink to the grassroots level to benefit more patients. "With this idea in mind, we will continue to research and develop 5G remote robot surgery to contribute to the balanced distribution of medical resources and the effective sharing of medical resources.